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“Transient receptor potential” cation channels (TRP channels) play a unique role as cell sensors, are involved in a plethora of Ca2+-mediated
cell functions, and play a role as “gate-keepers” in many homeostatic processes such as Ca2+ and Mg2+ reabsorption. The variety of functions to
which TRP channels contribute and the polymodal character of their activation predict that failures in correct channel gating or permeation will
likely contribute to complex pathophysiological mechanisms. Dysfunctions of TRPs cause human diseases but are also involved in a complex
manner to contribute and determine the progress of several diseases. Contributions to this special issue discuss channelopathias for which
mutations in TRP channels that induce “loss-“ or “gain-of-function” of the channel and can be considered “disease-causing” have been identified.
The role of TRPs will be further elucidated in complex diseases of the intestinal, renal, urogenital, respiratory, and cardiovascular systems. Finally,
the role of TRPs will be discussed in neuronal diseases and neurodegenerative disorders.
© 2007 Elsevier B.V. All rights reserved.Keywords: TRP channel; Channelopathy; Hereditary disease; Systemic disease; Transgenic model1. Introduction
The transient receptor potential (TRP) superfamily com-
prises now 28 mammalian cation channels which are sub-
divided – based on structural homology – into six subfamilies.
TRP channels are expressed in almost every tissue and cell type,
are activated by a plethora of different mechanisms and play an
important role in various cell functions. TRP channels play an
important role the pathogenesis of several human diseases [1–
4]. This special issue provides in-depth reviews of the impact of
TRP channels on some inherited and systemic diseases.
Because of our limited knowledge of TRP channel function in
native tissues, we are still at the very beginning of mechan-
istically understanding the role of TRPs in diseases. Only a few
channelopathias in which defects in trp genes directly cause
cellular dysfunction have been identified. Other indications of a
crucial role of TRPs in diseases arise from our knowledge of
TRP channels as targets for irritants, toxins, inflammation
products, and xenobiotics and finally from the correlation⁎ Tel.: +32 16 34 5937; fax: +32 16 34 5991.
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doi:10.1016/j.bbadis.2007.02.002between levels of channel expression and disease symptoms.
Without any doubt, TRPs are important players in several
human diseases and provide novel targets for pharmacological
intervention. However, we are still confronted with the sparse in
vivo studies, the lack of selective tools with which to modulate
and even to trace TRPs, and the limited answers from studies in
transgenic animals. Therefore, this special issue will also try to
critically balance hopes and obstacles. How far can we go to
accept TRP channels as critical players in human diseases and
novel pharmacological targets?
2. TRP channels: the basics
Transient receptor potential (TRP) channels are cation
channels, which act as cellular sensors in many cells types,
are involved in ion homeostasis by providing route for
transcellular transport, and are involved in the regulation of
the function of intracellular organelles. Most of them provide
Ca2+ entry pathways, which contribute to the regulation of a
plethora of Ca2+-dependent cell functions ranging from gene
transcription and cell death. Likely, no cell in our body is devoid
of TRPs. Topologically, each TRP channel subunit consists of
six putative transmembrane spanning segments (S1–6), a pore-
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NH2 and –COOH termini. Assembly of channel subunits as
homo- or hetero-tetramers results in the formation of cation
selective channels. Based on amino acid homology, the TRP
superfamily can be divided into seven subfamilies (see Fig. 1)
(see for detailed reviews [2,3,5,6, 7,8,9,10,11,12,13], series of
books and special issues [14], “TRP channels: Facts, Fiction,
Challenges,” Cell Calcium 33, 2003; “Functional Role of TRP
Channels” Pflügers Archive Eur J Physiol, 451, 2005), and also
data bases such as Ensemble Genome Browser at http://www.
ensembl.org/). The TRPC (canonical) subfamily consists of
seven (TRPC1–7) and the TRPM (melastatin) subfamily of
eight different channels (TRPM1–8). The TRPV (vanilloid)
subfamily presently comprises six members (TRPV1–6) and
the most recently discovered subfamily, TRPA (ankyrin), has
only one mammalian member (TRPA1). The TRPP (polycystin)
and TRPML (mucolipin) families, each containing 3 mamma-
lian members, are relatively poorly characterized, but are
attracting increasing interest because of their involvement in
several human diseases.
Most of the functionally characterized TRP channels are
non-selective Ca2+-permeable cation channels. Only TRPM4
and TRPM5 are only permeable to monovalent cations but not
to Ca2+ or Mg2+. Two mammalian TRPs, TRPV5 and TRPV6,
are highly Ca2+ permeable. TRPM6 and TRPM7 are highly
permeable to Mg2+. At least three TRP channels, TRPV1,
TRPML1, and TRPP3, are also highly permeable to H+ ions.
As far as gating of TRP channels is concerned, no unifying
mechanism exists. Characteristically, most of the TRP channels
can be activated by various chemical or physical stimuli, such as
ligand binding, temperature, changes in osmolarity or cell
volume, mechanical forces, or voltage. Some TRP channels
(such as TRPV5, TRPV6, and probably TRPA1) are constitu-
tively open, although most of these data originate from
experiments in heterologous overexpression systems. TRPC
channels are gated via PLC activation, either directly by
diacylglycerol (DAG), such as TRPC2, TRPC3, TRPC6, andFig. 1. Phylogenetic tree of the mammalian (human) TRP channel superfamily.
TRPC (canonical), TRPM (melastatin), TRPV (vanilloid), TRPA (ankyrin),
TRPP (polycystin), and TRPML (mucolipin). trpc2 is a pseudogene in humans.TRPC7, or indirectly via still not yet identified mechanism
(TRPC1, TRPC4, TRPC5). Indeed, TRPC1, TRPC4, and
TRPC5, which are activated by receptor-induced PLC, are
completely unresponsive to DAG [37,38]. The mechanisms by
which PLC activates these channels remain controversial.
Several TRP channels are activated by changes in tempera-
ture, e.g., by heat (TRPV1, TRPV2, TRPV3, TRPV4, TRPM2,
TRPM4, TRPM5) or by cold (TRPM8, and probably indirectly
TRPA1). Other TRP channels have recently been identified,
although not yet generally accepted, as mechano-sensor chan-
nels (TRPC1, TRPC6, TRPP2, TRPV4, TRPV2?; TRPM4?,
TRPM7?) or as channels activated by hyposmotic cell swelling
(TRPV2, TRPV4, TRPM3) or cell shrinking (TRPA1). The role
of TRPA1 as a mechano-sensor channel is still under debate. At
least two TRP channels can be gated by a decreased in pH:
TRPV1 and TRPP3. For most of the TRP channels, activating
ligands have been discovered and are endogenous (e.g., for
TRV1 endocannabinoids such as anandamide; see Tables 1 and
2), derived from natural compounds such as black pepper,
camphor, oregon, or carvacrol with as best-studied examples
capsaicin for TRPV1 and menthol for TRPM8, or purely syn-
thetic compounds (e.g., the phorbol 4α-phorbol 12,13-dide-
canoate for TRPV4).
Tables 1 and 2 summarize some essential properties of TRP
channel, which might be helpful for the following articles.
3. The TRP channel family and diseases
Defects in ion channel function have an increasing impact
on our understanding of several diseases. Diseases caused by
channel dysfunction are known as channelopathias. Of the
approximately 300 ion channels predicted in the human
genome (http://www.ncbi.nlm.nih.gov/RefSeq; http://www.
celeradiscoverysystem.com), relatively few have been directly
connected to human diseases [55,56]. For a series of more ge-
neral reviews on the role of TRP channels in disease see [1–4].
In this special issue, TRP channelopathias which link defects
in the gene encoding the channels with a disease or disease
symptoms are described. Six TRP channel-related channelo-
pathies in which mutants in the gene cause “loss-of-function” or
“gain-of-function” ion channels have been identified to date
(see Table 3 and the detailed reviews in this special issue for
focal segmental glomerulosclerosis TRPC6, mucolipidosis
type IV TRPML1, hypomagnesemia with secondary hypocal-
cemia TRPM6, polycystic kidney disease TRPP1/TRPP2,
aromatase excess syndrome TRPM7, and eventually Guama-
nian amyotrophic lateral sclerosis (ALS-G) and Guamian
Parkinsonism dementia (PD-G) TRPM7). Other diseases can
be provoked by changes in channel abundance, or channel
sensitization, or desensitization, resulting in potentiated or
abolished responses to pathological stimuli. Production of
endogenous ligands for TRP channels during the development
of a disease, e.g., during inflammation, can affect channel
function and cause diseases. The involvement of TRPV1 in
pain reception and the generation of neuropathic pain give an
excellent example of how mechanisms of modulation of
channel activity can cause and affect the development of many
Table 1
Some properties of the TRPC and TRPV family members
Permeation Proposed activation mechanisms
TRPC1 ENSG00000144935 nonselective, Ca2+ permeable phospholipase C (PLC), 1-oleoyl-2-acetyl-sn-glycerol (OAG),
mechanical (stretch), phosphoinositide-3 kinase (PI3K),
calmodulin, tyrosine-kinase receptor (TKR)-PLCγ,
upregulated by hypoxia-inducible factor (HIF-1), PKC,
NO?, store depletion?
TRPC2 ENSMUSG00000058020 nonselective, Ca2+ permeable PLC, diacylglycerol (DAG), store depletion?
TRPC3 ENSG00000138741 nonselective, Ca2+ permeable PLC, DAG, OAG, brain-derived growth factor (BDNF)—TKR-PLCγ,
tyrosine protein kinase Src, inositol (1,4,5) trisphosphate receptor (IP3-R),
orexin receptor OX1R, store depletion?; inhibited by NO and protein
kinase G (PKG),
TRPC4 ENSG00000100991 nonselective, Ca2+ permeable PLC, GTPγS, micromolar La3+, NO? Store depletion?
TRPC5 ENSG00000072315 nonselective, Ca2+ permeable PLC, GTPγS, receptor-operated, lysophosphatidylcholine (LPC),
micromolar La3+ or Gd3+, store depletion? [Ca2+]e, modest elevation
of [Ca2+]i, phosphatidylinositol 4-phosphate 5-kinase (PIP5K),
Rho GTPases (e.g. Rac1), PI3K), yosin light chain kinase (MLCK),
NO nitrosylation of pore cysteines
TRPC6 ENSG00000137672 nonselective, Ca2+ permeable PLC, DAG, OAG, Src, 20-hydroxyeicosatetraenoic acid (20-HETE,)
tyrosine kinase Fyn, Ca2+—Camodulin kinase II (CamK-II),
mechano-activated, AlF4
−, flufenamate; inhibited by the tarantula
peptide toxin GsMTx-4,
TRPC7 ENSG00000069018 nonselective, Ca2+ permeable PLC?, DAG, OAG, 20-HETE, store depletion?
TRPV1 ENSG00000043316 nonselective, Ca2+ permeable Depolarization, heat (≥43 °C), low pH (≤5.9), vanilloids,
endovanilloids, protein kinase C (PKC), CamK-II, PI(3)kinase,
activated by cyclin-dependent kinase (Cdk)-5, anandamide,
nerve growth factor (NGF), glia-derived growth factor (GDGF),
neurotropin 3 (NT3), reducing agents like dithiothreitol (DTT),
sensitization by ethanol, jelly fish toxin, venoms of the Indian
tarantulas contain inhibitor cysteine knot peptides (ICK),
12/15-hydroperoxyeicosatetraenoic acid (12-(S)-HPETE,
15-(S)-HPETE), 5-(S)-HETE, leukotriene B4, N-arachidonoyl
dopamine (NADA), protease-activated receptor 2 (PAR2), spermine,
2-aminoethoxydiphenyl borate (2-APB), oleoylethanolamide (OEA),
protein kinase A (PKA), PGE2 and PGI2 via their receptor EPI or IP;
metabotropic 5-hydroxytryptamine (5HT) receptors, 5HT2AR and 5HT7R,
decreased PI(4,5)P2 (?)(PIP2 also activates directly), inhibited by stretch
(short splice variant)
TRPV2 ENSG00000154039 nonselective Ca2+ permeable Noxious heat (>53 °C), mechanical (stretch, swelling),PKC, PI(3)K,
growth factors, insulin growth factor 1 (IGF-1), head activator (HA), 2-APB
TRPV3 ENSG00000167723 nonselective Ca2+ permeable Heat (23–29 °C), PKC, camphor, carvacrol, 2-APB, voltage dependent
TRPV4 ENSG00000111199 nonselective Ca2+ permeable Moderate heat (>24°C), cell swelling, shear stress, PLA2 activation, PKC,
PAR2, anandamide, epoxyeicosatrienoic acid (EETs), 4α-phorbol
12,13-didecanoate (4α-PDD) and other phorbols, bisandrographolide
A (BAA, from a Chinese herb)
TRPV5 ENSG00000127412 highly Ca2+ selective Low [Ca2+]i, hyperpolarization, voltage dependent block by Mg
2+,
calbindin D28 prevents channel inactivation, serum- and glucocorticoid
dependent kinase 1 (SGK1), serine/threonine kinase WNK4
TRPV6 ENSG00000165125 highly Ca2+ selective Low [Ca2+]i, hyperpolarization, voltage dependent block by Mg
2+, Src
For relevant data bases see also the Ensemble Genome Browser at http://www.ensembl.org/. The respective TRP numbers are included. Some inhibitory effects in are
mentioned in italics. For further details and references please refer to the reviews [15–24]. For more information on all TRP channels see [11,13,14,25–28], the
excellent guides to TRP channels on the David Clapham laboratory website at http://www.clapham.tch.harvard.edu/, the very comprehensive and instructive tables in
[29], and the special issue: “TRP channels: Facts, Fiction, Challenges”, Cell Calcium 33, 2003, “Functional Role of TRP Channels” Pflügers Archive Europ J Physiol,
451, 2005, “TRP channels as novel pharmacological targets”, Naunyn Schmiedebergs Arch Pharmacol, 371, 2005. For members of the TRPV family, see for details the
reviews of [30–36].
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channels and will therefore be able to sense many disturbances
in several forms of cellular homeostasis.
In general, dysregulation of TRP channel function may lead
to diseases by one or more of the following mechanisms:
• Most TRP channels play a role in Ca2+ signaling. Given the
universal role of Ca2+ as a signaling molecule, dysfunctionsin Ca2+ signaling due to altered TRP channel function can
have strong effects on a variety of cellular and systemic
processes. One reasonably understood example is the gain-
of-function of TRPC6 in the pathogenesis of cardiac
hypertrophy, in which an increased Ca2+ influx couples via
calciceurin to NFAT activation [57].
• TRP channels can act as general polymodal cellular sensors,
measuring changes in the environment to initiate adequate
Table 2
Some important properties of the TRPM, TRPML, TRPP, and TRPA family members
Permeation Proposed activation mechanisms
TRPM1 ENSG00000134160 n.d. Translocation, microphthalmia-associated
transcription factor (MITF) induced expression
TRPM2 ENSG00000142185 nonselective, Ca2+ permeable ADP-ribose, cyclic ADP-ribose at higher temperatures,
nicotinamide adenine dinucleotide (NAD), heat, H2O2
and other reactive oxygen species (ROS), poly(ADP)ribose
polymerase-1 (PARP-1), Ca2+, NAD dependent deacetylases,
sirtuins
TRPM3 ENSG00000083067 nonselective, Ca2+ permeable Cell swelling, store depletion?, D-erythrosphingosine,
steroid hormones (pregnenolone derivatives)
TRPM4 ENSG00000130529 Selective for monovalent cations,
Ca2+ impermeable
Elevated [Ca2+]i, ATP, PKC, decavanadate, voltage dependent,
heat, PI(4,5)P2, 3,5-bis(trifluoromethyl)pyrazole (BTP2),
TRPM5 ENSG00000070985 Selective for monovalent
cations, Ca2+ impermeable
Elevated [Ca2+]i, phosphatidylinositol (4,5) bisphosphate
(PI(4,5)P2) Voltage dependent, heat, arachidonic acid
TRPM6 ENSG00000119121 highly Mg2+ permeable,
Ca2+ permeable
Decreased [Mg2
+
]i, 2-APB
TRPM7 ENSG00000092439 highly Mg2+ permeable,
Ca2+ permeable
Decreased [Mg2
+
]i, Mg-ATP, PI(4,5)P2, cAMP, G-proteins,
PKA, Src, shear stress, stretch, membrane translocation
TRPM8 ENSG000000144481 nonselective, Ca2+ permeable Depolarization, cold (8–28 °C), menthol, icilin, increased
intracellular pH, PI(4,5)P2, lysophosphatides (LP's)
TRPML1 ENSG00000090674 H+ permeable Increased [Ca2+]i, inhibited by proteolytic cleavage
TRPML2 ENSG00000153898 n.d. n.d.
TRPML3 ENSG00000055732 n.d. low pH
TRPP2 ENSG00000118762 nonselective, Ca2+ permeable mechanical stress, [Ca2+]i
TRPP3 ENSG00000107593 nonselective, Ca2+ permeable [Ca2+]i, activated by low pH when expressed with PKD1L3.
TRPP5 ENSG00000078795 nonselective, Ca2+ permeable [Ca2+]i
TRPA1 ENSG00000104321 nonselective, Ca2+ permeable Isothiocyanates, allicin, Δ9-tetrahydrocannabinol (THC),
cinnamaldehyde, prolonged noxious cold?, mechanical stress,
voltage dependent ?, [Ca2+]i dependent, OAG and arachidonic
acid downstream of receptor-mediated PLC activation, menthol?,
thymol, carvacrol, acrolein, artemin (a neuronal survival factor),
covalent modification of N-terminal cysteines activates
For references for channel names, numbering, and additional information, see the note to Table 1 (some inhibitory effects in italics). For details and references, please
refer to the relevant reviews [28,39–45]. Note that TRPM4 data listed are for TRPM4b. Some important properties of members of the TRPP and TRPML families, as
well as of TRPA1, are listed. Relevant reviews for TRMLs are [46–48]; for TRPPs see [9,48–53]; for TRPA see [54].
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sensory inputs may cause multiple forms of cellular and
somatosensory dysregulation.
• Some TRP channels function as gatekeepers for the selec-
tive (re)absorption of ions such as Mg2+ and Ca2+. Dys-
function will lead to general disturbances in Mg2+ and
Ca2+ homeostasis.
• TRP channels are present on intracellular membranes, where
their malfunctioning may lead to disturbed organelle
function. One clear example is the deregulation of lysosome
function due to mutations in TRPML1 [47].
• Some TRP channels play an important role in the trafficking
of interacting proteins. Mistargeting of these binding
partners may underlie a variety of pathological conditions.
• Several TRP channels are involved in the control of cell
proliferation and growth. Dysfunctions may lead to growth
disturbances, altered organogenesis, or cancer.
• TRP channels have the potential to modulate the electrical
activity of excitable cells, e.g., in brain and heart. Investigat-
ing the consequences of TRP channel dysfunction on
electrically complex cell functions such as generation of
spontaneous electrical activity is an important challenge for
future research.Our restricted knowledge about the function of many TRP
channels and the paucity of selective modulators hamper our
understanding of the mechanistic role of TRP channels in
human disease and also the development of TRP targeting
drugs. So far, the best understood TRP channel is TRPV1, and a
plethora of blocking compounds are available for the treatment
of different forms of pain (see this special issue and also, e.g.,
Ref. [58]). Another promising example concerns TRPC1. This
channel is up-regulated in smooth muscle cells in occlusive
vascular disease. Inhibitory antibodies of TRPC1 have the
potential of acting as protective agents against human vascular
failure [59]. Some other trials using functional antibodies are
anticipated [60].
A role for several TRP channels in the ontogeny of diseases
can be suspected based on the chromosomal localization of the
encoding genes. The chromosomal localizations of all TRP
genes and some relevant diseases linked to these loci are sum-
marized in detail in an excellent review [1]. However, also we
know these “thy neighbors,” causal pathogenic mechanisms,
have not yet been established (see also OMIM data base at
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi%3Fdb%3DOMIM).
Finally, this introduction presents a table listing TRPs
that cause diseases or contribute to their progression. Table
Table 3
Proposed functions of TRPs, chromosomal localization, and possible relationships to diseases (adapted from [3] used with permission)
(continued on next page)
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Table 3 (continued)
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Table 3 (continued)
For details and references see text. Functional evidence of possible disease connections obtained from transgenic mouse models is marked in red. n.d., not determined.
For more possible associations between TRP channels and disease based on genomic localisation see http://www.ncbi.nlm.nih.gov/entrez/query.fcgidb%3DOMIM,
[14], and especially [1].
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expert articles which will provide detailed insight into some
of the here-listed connections between TRPs and diseases.
4. Conclusion
In this the roles of some TRP channels in human diseases
are described by leading scientists in this field. The
involvement of TRPs in a plethora of fundamental cell
functions urges the investigation of their role in human
pathophysiology and disease. Undoubtedly, these studies,
linking TRP function to disease, will become an important
priority in biomedical sciences. This special issue is also
intended to describe these channels as novel and important
targets for the development of new drugs. Needless to say, we
have just entered an exciting and fast advancing field of ion
channel research.
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